165 related articles for article (PubMed ID: 23727913)
1. Change in the character of liposomes as a drug carrier by modifying various polyethyleneglycol-lipids.
Sugiyama I; Sadzuka Y
Biol Pharm Bull; 2013; 36(6):900-6. PubMed ID: 23727913
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
Sugiyama I; Sadzuka Y
Int J Pharm; 2013 Jan; 441(1-2):279-84. PubMed ID: 23194885
[TBL] [Abstract][Full Text] [Related]
3. Correlation of fixed aqueous layer thickness around PEG-modified liposomes with in vivo efficacy of antitumor agent-containing liposomes.
Sugiyama I; Sadzuka Y
Curr Drug Discov Technol; 2011 Dec; 8(4):357-66. PubMed ID: 22034853
[TBL] [Abstract][Full Text] [Related]
4. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome.
Sadzuka Y; Nakade A; Hirama R; Miyagishima A; Nozawa Y; Hirota S; Sonobe T
Int J Pharm; 2002 May; 238(1-2):171-80. PubMed ID: 11996821
[TBL] [Abstract][Full Text] [Related]
5. [To Assess Drug Delivery System Nanocarrier at Industrial Production: Establishment of Liposomal Surface Using Physicochemical Properties].
Sadzuka Y
Yakugaku Zasshi; 2024; 144(1):61-69. PubMed ID: 38171797
[TBL] [Abstract][Full Text] [Related]
6. Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin.
Sadzuka Y; Sugiyama I; Tsuruda T; Sonobe T
Int J Pharm; 2006 Apr; 312(1-2):83-9. PubMed ID: 16457972
[TBL] [Abstract][Full Text] [Related]
7. [Characterization and cytotoxicity of mixed PEG-DSG modified liposomes].
Sadzuka Y; Tsuruda T; Sonobe T
Yakugaku Zasshi; 2005 Jan; 125(1):149-57. PubMed ID: 15635286
[TBL] [Abstract][Full Text] [Related]
8. Effect of Liposomes with Different Double Arms Polyethyleneglycol on Hepatic Metastasis Model Mice and Evaluation Using a Fluorescent Imaging Device.
Sugiyama I; Oikawa H; Masuda T; Sadzuka Y
Curr Drug Deliv; 2017; 14(5):668-675. PubMed ID: 27017825
[TBL] [Abstract][Full Text] [Related]
9. Characterization of novel mixed polyethyleneglycol modified liposomes.
Sugiyama I; Sadzuka Y
Biol Pharm Bull; 2007 Jan; 30(1):208-11. PubMed ID: 17202690
[TBL] [Abstract][Full Text] [Related]
10. Effect of polyethyleneglycol (PEG) chain on cell uptake of PEG-modified liposomes.
Sadzuka Y; Kishi K; Hirota S; Sonobe T
J Liposome Res; 2003 May; 13(2):157-72. PubMed ID: 12855110
[TBL] [Abstract][Full Text] [Related]
11. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D
AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957
[TBL] [Abstract][Full Text] [Related]
12. Effect of hybridized liposome by novel modification with some polyethyleneglycol-lipids.
Sugiyama I; Sonobe T; Sadzuka Y
Int J Pharm; 2009 May; 372(1-2):177-83. PubMed ID: 19429278
[TBL] [Abstract][Full Text] [Related]
13. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin.
Sadzuka Y; Nakade A; Tsuruda T; Sonobe T
J Control Release; 2003 Sep; 91(3):271-80. PubMed ID: 12932707
[TBL] [Abstract][Full Text] [Related]
14. [PEG-liposome in DDS and clinical studies].
Maruyama K
Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
[TBL] [Abstract][Full Text] [Related]
15. A novel liposome surface modification agent that prolongs blood circulation and retains surface ligand reactivity.
Ishihara A; Yamauchi M; Tsuchiya T; Mimura Y; Tomoda Y; Katagiri A; Kamiya M; Nemoto H; Suzawa T; Yamasaki M
J Biomater Sci Polym Ed; 2012; 23(16):2055-68. PubMed ID: 22054261
[TBL] [Abstract][Full Text] [Related]
16. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU).
Park SM; Kim MS; Park SJ; Park ES; Choi KS; Kim YS; Kim HR
J Control Release; 2013 Sep; 170(3):373-9. PubMed ID: 23770213
[TBL] [Abstract][Full Text] [Related]
17. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.
Boakye CH; Patel K; Singh M
Int J Pharm; 2015 Jul; 489(1-2):106-16. PubMed ID: 25910414
[TBL] [Abstract][Full Text] [Related]
20. [An importance of colloid chemical characterization of liposomes for DDS in a large scale production].
Hirota S
Yakugaku Zasshi; 1997 Dec; 117(12):991-1005. PubMed ID: 9437906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
